Skip to main content
An official website of the United States government
NIH Websites Are Changing
Per Executive Order 14434, federal agencies are now using "Super Intelligence" (SI) in place of "Artificial Intelligence" (AI). You may see both terms across NIH content during this transition.

actinium Ac 225-DOTA-h11B6 JNJ-69086420

A radioimmunoconjugate containing h11B6, a humanized immunoglobulin G1 (IgG1) monoclonal antibody that targets human kallikrein-2 (hK2), conjugated with the bifunctional, macrocyclic chelating agent tetra-azacyclododecanetetra-acetic acid (DOTA), and labeled with the alpha-emitting radioisotope actinium Ac 225, with potential antineoplastic activity. Upon administration of actinium Ac 225-DOTA-h11B6 JNJ-69086420, the monoclonal antibody moiety of JNJ-69086420 targets and binds to hK2, thereby delivering a cytotoxic dose of alpha radiation to hK2-expressing tumor cells. hK2 is overexpressed on a variety of cancer cells.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:[225Ac]-DOTA-h11B6
225Ac-h11B6 JNJ-69086420
actinium-225-labeled anti-kallikrein-2 h11B6 JNJ-69086420
actinium-225-labeled h11B6 JNJ-69086420
Code name:JNJ 69086420
JNJ-69086420
JNJ69086420
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search